Navigation Links
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Date:5/27/2008

open to both treatment-naive and previously treated patients, ultimately enrolling a much larger treatment-naive population (78%). Patients were randomized at a one-to-one ratio to receive either Specifid or placebo following a standard course of Rituxan. The trial was conducted at 67 centers in the U.S.

Conference Call and Webcast

Favrille's management team will host a conference call today at 8:30 a.m. Eastern Time to discuss the information contained in this press release. A live audio webcast will be available on the Investor Relations section of the Company's web site at http://www.favrille.com . Alternatively, callers may participate in the conference call by dialing (866) 831-6267 or (617) 213-8857, passcode 99549869. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 20389415.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securiti
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille Reports First Quarter 2008 Financial Results
2. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
3. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
4. Favrille Announces $21.1 Million Registered Direct Offering
5. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
6. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
7. Favrille to Present at BIO InvestorForum
8. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
9. Favrille CEO to Present at Bear Stearns Healthcare Conference
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... Pharmaceuticals, Inc. (NYSE: WPI ) today announced ... from the United States Food and Drug Administration on ... tablets, the generic equivalent to Roche,s BONIVA® tablets. Watson ... quarter. BONIVA® 150mg tablets had total U.S. sales of ...
... 2012 Creative Bioscience, a leading maker of dietary supplements ... African Mango Lean ™, African Mango 1200 ™, ... and its new Raspberry Ketone 1234 ™ weight loss ... Markets locations across the West and Southwest. ...
...  The San Diego entrepreneur group Bootstrappers Breakfast ( www.bootstrappersbreakfast.com ... a.m. on the last Friday of every month. The ... breakfast" is Friday, March 30 at 7:30 a.m. at ... Attendees, all with an entrepreneurial streak, discuss innovative ways to ...
Cached Biology Technology:Watson's Generic BONIVA® 150mg Receives FDA Approval 2Creative Bioscience All-Natural Dietary Supplements Now Available at Sprouts Farmers Market 2Creative Bioscience All-Natural Dietary Supplements Now Available at Sprouts Farmers Market 3Entrepreneurs to Eat Problems for Breakfast in San Diego 2
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center today ... School of Medicine. Funding for this $50 million capital project ... publicly launched next summer. The medical education ... Reynolds Tobacco Company complex, adjacent to 525@vine in Wake Forest ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... 2, 2012 Biochemist and geneticist Alexander Varshavsky (California Institute ... lived in the USA since 1977, has been awarded the ... Molecular Biology (GBM). That medal is considered to be the ... By means of genetic research carried out with yeast and ...
... among his most vibrant and celebrated works, Vincent van Gogh,s ... basis has, until now, been a mystery. In a study ... of Georgia scientists reveal the mutation behind the distinctive, thick ... more than 100 years ago. The most common sunflower ...
... parasite, less resistance can sometimes be better than more, a ... known as Daphnia dentifera endures periodic epidemics of ... percent of the Daphnia population. During these epidemics, the ... A new study led by Georgia Institute of Technology ...
Cached Biology News:Otto Warburg Medal for Alexander Varshavsky 2Otto Warburg Medal for Alexander Varshavsky 3Genetic mutation depicted in van Gogh's sunflower paintings revealed by scientists 2Weakness can be an advantage in surviving deadly parasites, a new study shows 2Weakness can be an advantage in surviving deadly parasites, a new study shows 3
... Art GLP facility with capabilities from ... fermentation. Coordinated process development from ... operation capable of simultaneous production runs ... Hosts include: Bacteria, Yeast, Fungi, ...
Request Info...
Immunogen: VDAC3 Protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
... 75 x 25 ... recommended for immunohistochemistry of paraffin-embedded sections, ... one end, markings will ... procedures, precleaned, ...
Biology Products: